Previous 10 | Next 10 |
Celldex Therapeutics ( CLDX ) is a development stage pharmaceutical company. It was once a high flyer, reaching the equivalent of $402.15 per share in 2015 before its lead candidate failed a Phase 3 trial. More recently, before the CDX-0159 news was announced, it was selling at about $3.00 per...
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public off...
Are These On Your List Of Penny Stocks Right Now? Do you know where to buy penny stocks ? If you’re new to stocks under $5, then it’s a valid question. To be honest, the options available in the stock market today are plentiful. Just look for some of the top penny stock brokers...
Gainers: Wah Fu Education (NASDAQ: WAFU ) +257% . More news on: Wah Fu Education Group Limited, Wins Finance Holdings Inc., Celldex Therapeutics, Inc., Stocks on the move, , Read more ...
Gainers: Wins Finance (NASDAQ: WINS ) +252% . More news on: Wins Finance Holdings Inc., DPW Holdings, Inc., Curis, Inc., Stocks on the move, , Read more ...
DPW Holdings DPW +198% on $3.2M of defense orders . More news on: Plus Therapeutics, Inc., Genius Brands International, Inc., Fang Holdings Limited, Stocks on the move, , Read more ...
Celldex Therapeutics (NASDAQ: CLDX ) announces results from a randomized, double-blind, placebo-controlled, dose-escalation Phase 1 clinical trial evaluating KIT inhibitor CDX-0159 in 32 healthy volunteers. More news on: Celldex Therapeutics, Inc., Healthcare stocks news, Stocks on the...
--Data strongly support expanding development into mast cell driven diseases-- --Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the Company...
Celldex (NASDAQ: CLDX ): Q1 GAAP EPS of -$0.73 misses by $0.03 . Revenue of $2.7M (+88.8% Y/Y) beats by $1.71M . Shares +0.8% . Press Release More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make co...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...